Dupixent® (dupilumab) positive phase 3 data in children 1 to 11 years of age with eosinophilic esophagitis published in the new england journal of medicine

Majority of patients in this age group with eosinophilic esophagitis (eoe) receiving dupixent achieved histologic remission, with improvements sustained up to one year

REGN Ratings Summary

REGN Quant Ranking